Ridgemont Equity Partners Acquires Majority Interest in Gallus BioPharmaceuticals

May 19, 2011

Charlotte, NC (May 18, 2011) – Ridgemont Equity Partners (“Ridgemont”), a middle market buyout and growth equity firm, today announced the closing of a majority investment in partnership with management in Gallus Biopharmaceuticals, LLC (“Gallus” or the “Company”), a premier biologics contract manufacturing organization based in St. Louis, MO. The financial terms of the transaction were not disclosed.

Gallus is a contract manufacturer of clinical and commercial-grade bulk biologics products. The investment from Ridgemont facilitated Gallus’ acquisition of an existing FDA-approved, commercially-certified biologics manufacturing plant from Centocor Biologics, LLC. The plant currently manufactures two of Centocor Biologics’ leading products, Remicade and Stelara, which are distributed globally. Ridgemont’s investment will also be used to expand the facility’s manufacturing capabilities, including building a clinical services suite and expanding the existing development lab.

Gallus is led by President and CEO Mark Bamforth, a former executive with Genzyme Corp., along with an experienced team of senior executives including Shelly Adams, Vice President of Sales and Marketing, Steven Kasok, Chief Financial Officer and Mark Bell, Vice President of Site Operations.

“We are delighted to partner with the Ridgemont team,” said Mark Bamforth, President and CEO of Gallus. “Ridgemont’s experience in healthcare was particularly attractive to us as we sought the best investor to help us execute our growth strategies and achieve our goal of becoming a leading biologics contract manufacturing partner providing innovative, flexible manufacturing solutions to biopharmaceutical companies.”

“We are extremely pleased to form a partnership with Mark Bamforth and his senior leadership team,” said Jack Purcell, a Principal at Ridgemont who will join the Gallus Board of Directors. “We see a tremendous market opportunity in the biologics contract manufacturing space and believe the facility we’ve acquired is well-positioned to meet the current and future market needs of our customers.”

“The Ridgemont team has a nearly two decade-long history of successfully investing in healthcare and industrials transactions, and we expect that experience to be particularly relevant in helping Gallus grow over the life of our investment in the Company,” said Walker Poole, a Partner at Ridgemont, who will also join the Gallus Board of Directors. “We plan to build upon our past success with a contract manufacturer of pharmaceutical products, which was a very successful investment for our firm.”

Doug Bauche, President of St. Charles region at Enterprise Bank & Trust said “Enterprise is very pleased to partner with Gallus and Ridgemont in providing the senior financing necessary to complete the acquisition of the Centocor facility. The investment being made by Gallus and Ridgemont here in St. Louis is significant in many respects. The retention of jobs and investment in additional plant and equipment makes this a big win for our community.”

Missouri Governor Jay Nixon visited the Gallus facility on Wednesday, May 18 to participate in an official ribbon-cutting ceremony.

About Gallus Biopharmaceuticals:

Gallus Biopharmaceuticals is a premier biologics contract manufacturing organization based in St. Louis, MO. Gallus operates an FDA-approved, commercially-certified facility formerly owned by Centocor Biologics, LLC. The Gallus facility has capabilities for mammalian cell culture and protein purification in both perfusion and fed batch mode and will expand to offer additional development and clinical services capabilities. The plant currently produces two leading commercial biologics products, distributed globally. www.gallusbiopharma.com.

About Ridgemont Equity Partners:

Ridgemont Equity Partners is a Charlotte-based private equity firm that specializes in middle market buyout and growth equity investments. Since 1993, the principals of Ridgemont have invested over $3 billion in more than 140 companies. The firm focuses on investments of $25 million to $75 million in industries in which it has deep expertise, including basic industries and services, energy, healthcare, and telecommunications/ media/ technology. www.ridgemontep.com.


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.